Pancreas_cancer

OncoGenex Pharmaceuticals has started enrolment in the investigator-sponsored Rainier Phase II trial of apatorsen (OGX-427) in combination with Abraxane plus gemcitabine in patients with metastatic pancreatic cancer.

The placebo-controlled trial, sponsored by the Sarah Cannon Research Institute (SCRI), will randomise around 130 patients with either apatorsen, paclitaxel protein-bound particles for injectable suspension, or placebo in combination with Abraxane and gemcitabine therapy.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Overall survival (OS) is the primary objective of the study, which is designed to further evaluate progression-free survival (PFS), tumour response rates, safety, tolerability, and the effect of therapy on heat shock protein 27 (Hsp27) levels.

Sarah Cannon Research Institute (SCRI) GI cancer research program director Dr Johanna Bendell said median survival for patients with advanced pancreatic cancer remains low and the institute needs to explore additional strategies to address treatment resistance.

"We are very excited to open enrolment in the Rainier trial, to explore the role of Hsp27 in pancreatic cancer and to evaluate for the potential ability of apatorsen to improve clinical outcomes for patients when added to combination chemotherapy," Bendell said.

See Also:

Conducted at approximately 12 sites in the US, Rainier is part of the ongoing studies evaluating treatment resistance in cancer (ORCA) programme encompassing clinical trials of apatorsen.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

A once-weekly intravenous (IV) experimental drug, apatorsen is designed to inhibit production of heat shock protein 27 (Hsp27) to disable cancer cells’ defenses and overcome treatment resistance.

Image: Micrograph of the most common type of pancreatic cancer. H&E stain. Photo: courtesy of KGH.